Metagenomic next-generation sequencing-guided antimicrobial treatment versus conventional antimicrobial treatment in early severe community-acquired pneumonia among immunocompromised patients (MATESHIP): A study protocol

Metagenomic next-generation sequencing-guided antimicrobial treatment versus conventional antimicrobial treatment in early severe community-acquired pneumonia among immunocompromised patients (MATESHIP): A study protocol

BackgroundSevere community-acquired pneumonia (SCAP) is the main cause of mortality in immunocompromised patients. Compared with conventional microbiological tests (CMT), metagenomic next-generation sequencing (mNGS) can quickly and simultaneously detect a wide array of bacteria, viruses, and fungi...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Shaohua Fan, Min Si, Nana Xu, Meichen Yan, Mingmin Pang, Guangfeng Liu, Jibin Gong, Hao Wang
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2022-08-01
Sarja:Frontiers in Microbiology
Aiheet:
metagenomic next generation sequencing
immunosuppression
immunocompromised patient
community-acquired pneumonia
antimicrobial therapy
Linkit:https://www.frontiersin.org/articles/10.3389/fmicb.2022.927842/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2022.927842/full

Samankaltaisia teoksia